NCT03132259

Brief Summary

Transnasal transsphenoidal (TNTS) resection of pituitary tumors involves wide fluctuation in hemodynamic parameter and causes hypertension and tachycardia due to intense noxious stimuli during various stages of surgery. None of routinely used anesthetic agents effectively blunts the undesirable hemodynamic responses, and therefore usually there is a need to use increased doses of anesthetic agents. Dexmedetomidine (DEX) an α-2 adrenergic receptor agonist, because its sympatholytic and antinociceptive properties may ensure optimal intraoperative hemodynamic stability during critical moments of surgical manipulation. In addition, DEX reduced the anesthetic requirement with rapid recovery at the end of surgery. The main aim of the study was to evaluate the effect of DEX on perioperative hemodynamics, anesthetic requirements

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
124

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started May 2016

Typical duration for phase_4

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2016

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

July 18, 2016

Completed
9 months until next milestone

First Posted

Study publicly available on registry

April 27, 2017

Completed
4 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2017

Completed
1.1 years until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2018

Completed
Last Updated

May 30, 2017

Status Verified

May 1, 2017

Enrollment Period

1 year

First QC Date

July 18, 2016

Last Update Submit

May 25, 2017

Conditions

Keywords

Dexmedethomidine

Outcome Measures

Primary Outcomes (1)

  • Comparative Low and High Dose of Dexmedethomidine in Pituitary Tumor Removal by Transphenoid Approach

    Low dose is 0.2microgram/kg/hr High dose is 0.5 microgram/kg/hr what is the dose proper and hemodynamic changes. Hemodynamic change means BP is lower than 20% of baseline more than 10minute

    24 hours

Secondary Outcomes (1)

  • Comparative Low and High Dose of Dexmedethomidine in Pituitary Tumor

    24 hours

Study Arms (2)

High dose dexmedethomidine

EXPERIMENTAL

High dose is 0.5 microgram/kg/hr

Drug: high dose dexmedethomidine

Low dose dexmedethomidine

EXPERIMENTAL

Low dose is 0.2 microgram/kg/hr

Drug: low dose dexmedethomidine

Interventions

Dexmedethomidine continuous drip 0.5 mcg/kg/hr a

Also known as: Precedex
High dose dexmedethomidine

Dexmedethomidine continuous drip 0.2 mcg/kg/hr

Low dose dexmedethomidine

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age18-65
  • ASA 1-2
  • Elective TNTS resection of Pituitary Tumor
  • No narcotic before surgery as premedication
  • Able to Extubate

You may not qualify if:

  • GCS less than 15
  • Preoperative Heart Rate less than 50 beat/min
  • No Beta-Blockers
  • Pregnant patients
  • Take any Alpha-Methyldopa, Clonodine, Other Alpha-2 Adrenergic Agonist
  • Hemodynamic unstable
  • Systolic BP more than 160mmHg
  • CAD
  • Renal insuffuciency
  • Allergy in dexmedethomidine and opioid
  • BMI more than 30
  • Denied consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Faculy of Medicine Siriraj hospital Mahidol University

Bangkok, 10700, Thailand

RECRUITING

Related Publications (4)

  • Gopalakrishna KN, Dash PK, Chatterjee N, Easwer HV, Ganesamoorthi A. Dexmedetomidine as an Anesthetic Adjuvant in Patients Undergoing Transsphenoidal Resection of Pituitary Tumor. J Neurosurg Anesthesiol. 2015 Jul;27(3):209-15. doi: 10.1097/ANA.0000000000000144.

  • Anjum N, Tabish H, Debdas S, Bani HP, Rajat C, Anjana Basu GD. Effects of dexmedetomidine and clonidine as propofol adjuvants on intra-operative hemodynamics and recovery profiles in patients undergoing laparoscopic cholecystectomy: A prospective randomized comparative study. Avicenna J Med. 2015 Jul-Sep;5(3):67-73. doi: 10.4103/2231-0770.160231.

  • Polat R, Peker K, Baran I, Bumin Aydin G, Topcu Guloksuz C, Donmez A. Comparison between dexmedetomidine and remifentanil infusion in emergence agitation during recovery after nasal surgery: A randomized double-blind trial. Anaesthesist. 2015 Oct;64(10):740-6. doi: 10.1007/s00101-015-0077-8. Epub 2015 Sep 2.

  • Karwacki Z, Niewiadomski S, Rzaska M, Witkowska M. The effect of bispectral index monitoring on anaesthetic requirements in target-controlled infusion for lumbar microdiscectomy. Anaesthesiol Intensive Ther. 2014 Sep-Oct;46(4):284-8. doi: 10.5603/AIT.2014.0046.

MeSH Terms

Conditions

Pituitary Neoplasms

Interventions

Dexmedetomidine

Condition Hierarchy (Ancestors)

Endocrine Gland NeoplasmsNeoplasms by SiteNeoplasmsHypothalamic NeoplasmsSupratentorial NeoplasmsBrain NeoplasmsCentral Nervous System NeoplasmsNervous System NeoplasmsBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesHypothalamic DiseasesPituitary DiseasesEndocrine System Diseases

Intervention Hierarchy (Ancestors)

ImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Officials

  • Saipin Muangman, physician

    Mahidol University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Saipin Muangman, physician

CONTACT

Sirinuttakul Akkaworakit, physician

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assisted Professor

Study Record Dates

First Submitted

July 18, 2016

First Posted

April 27, 2017

Study Start

May 1, 2016

Primary Completion

May 1, 2017

Study Completion

June 1, 2018

Last Updated

May 30, 2017

Record last verified: 2017-05

Locations